THE COMBINATION OF CDK4 AND MAPK/ERK PATHWAY INHIBITOR THERAPY IN MELANOMA: DEFINING MELANOMA CELL INTRINSIC AND IMMUNE MEDIATED RESPONSES
Grant number: 1100189 | Funding period: 2016 - 2019
Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments do not induce long term disease control. Thus newer types of treatment are required to treat more advanced melanomas. Our proposal will use a drug that stops melanoma cells from growing and in combination with other drugs causes the cells to release factors that activate the immune system to eliminate the tumour.
Related publications (3)
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Emily J Lelliott, Carleen Cullinane, Claire A Martin, Rachael Walker, Kelly M Ramsbottom, Fernando Souza-Fonseca-Guimaraes, Shatha Abuhammad, Jessica Michie, Laura Kirby, Richard J Young, Alison Slater, Peter Lau, Katrina Meeth, Jane Oliaro, Nicole Haynes, Grant A McArthur, Karen E Sheppard
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Claire A Martin, Carleen Cullinane, Laura Kirby, Shatha Abuhammad, Emily J Lelliott, Kelly Waldeck, Richard J Young, Natalie Brajanovski, Donald P Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Richard B Pearson, Rodney J Hicks, Grant A McArthur, Karen E Sheppard